Grade 3 adverse events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroidism (n=1). No serious adverse events were reported. Interpretation: To our knowledge, this is the first completed phase 2 trial of immunotherapy for SCCA.
Book Title: Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study
Author:
Published on 2017 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma treatment
Download Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study eBook
Background: Squamous cell carcinoma of the anal canal (SCCA) is a rare malignancy associated with infection by human papillomavirus (HPV). No consensus treatment approach exists for the treatment of metastatic disease. Because intratumoral HPV oncoproteins upregulate immune checkpoint proteins such as PD-1 to evade immune-mediated cytotoxicity, we did a trial of the anti-PD-1 antibody nivolumab for patients with metastatic SCCA. Methods: We did this single-arm, multicentre, phase 2 trial at ten academic centres in the USA. We enrolled patients with treatment-refractory metastatic SCCA, who were given nivolumab every 2 weeks (3 mg/kg). The primary endpoint was response according to Response Evaluation Criteria in Solid Tumors, version 1.1, in the intention-to-treat population. At the time of data cutoff, the study was ongoing, with patients continuing to receive treatment. The study is registered withClinicalTrials.gov, numberNCT02314169 . Results: We screened 39 patients, of whom 37 were enrolled and received at least one dose of nivolumab. Among the 37 patients, nine (24% [95% CI 15–33]) had responses. There were two complete responses and seven partial responses. Grade 3 adverse events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroidism (n=1). No serious adverse events were reported. Interpretation: To our knowledge, this is the first completed phase 2 trial of immunotherapy for SCCA. Nivolumab is well tolerated and effective as a monotherapy for patients with metastatic SCCA. Immune checkpoint blockade appears to be a promising approach for patients with this orphan disease. Funding: National Cancer Institute/Cancer Therapy Evaluation Program, the HPV and Anal Cancer Foundation, the E B Anal Cancer Fund, The University of Texas MD Anderson Moon Shots Program, and an anonymous philanthropic donor.
Our website offers free Carcinoma treatment Ebooks to download. Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma treatment and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma treatment ebooks free
download Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study that are available to have. Thinking of having Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study ebook? You are in the right place. Get the ebook Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study by: .
Book Details:
- Book was ranked at 3 by Google Books for Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study
- Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study published by since 2017 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=-UPdvQEACAAJ&dq=Carcinoma+treatment&hl=&cd=322&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): a Multicentre, Single-arm, Phase 2 Study by: ":
- Server 2: SECURE LINK